Showing 2771-2780 of 4166 results for "".
- Keck Medicine of USC to Open New Ambulatory Clinic in Southern California’s San Gabriel Valleyhttps://modernod.com/news/keck-medicine-of-usc-to-open-new-ambulatory-clinic-in-southern-californias-san-gabriel-valley/2480124/Keck Medicine of USC is expanding its network of ambulatory clinics with a new location in Southern California’s San Gabriel Valley. Located at 125 W. Huntington Drive in <
- BVI Medical Launches Educational Platform for Ophthalmology Professionalshttps://modernod.com/news/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/2482639/BVI Medical announced the launch of EyeXchange Solutions, a platform designed to enhance vision care through comprehensive educational resources and clinical support. This initiative aims to empower surgical decision-making, enhance provider experiences, alleviate economic
- Heidelberg Engineering to Showcase New Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-to-showcase-new-imaging-technology-at-arvo/2482254/At the upcoming ARVO meeting in Seattle, Heidelberg Engineering will showcase a wide range of imaging applications from basic vision research to clinical trials and guided therapy. SeeLuma For the first time, Heidelberg Engineering will demonstrate
- Trefoil Therapeutics Announces TTHX1114 Data Presentations at the ARVO 2023https://modernod.com/news/trefoil-therapeutics-announces-tthx1114-data-presentations-at-the-arvo-2023/2481536/Trefoil Therapeutics announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision
- Zeiss Launches New Frame and Lens Disinfecting Technology to Support Safety and Hygiene in Eye Care Practiceshttps://modernod.com/news/zeiss-launches-new-frame-and-lens-disinfecting-technology-to-support-safety-hygiene-and-productivity-in-eyecare-practices/2478262/Zeiss Vision Care US announced the launch of the
- Lifestyle Choices May Help Glaucoma Patients Preserve Eyesighthttps://modernod.com/news/lifestyle-choices-may-help-glaucoma-patients-preserve-eyesight/2476174/Glaucoma is one of the leading causes of vision loss, aff
- Live Webcast: COVID-19 Impact on Retina Practiceshttps://modernod.com/news/live-webcast-covid-19-impact-on-retina-practices/2477468/Bryn Mawr Communications (BMC) will host a live video webcast of its New Retina Radio podcast on Friday at 12 pm ET. The webcast, “How Retina Doctors Are Altering Their Treatments During the COVID-19 Crisis, and How They Can Anticipate What’s Next,” will be hosted by John W. Kitchens, MD. Panelis
- New Live Video Webcast Series Aims to Unite, Educate Ophthalmologistshttps://modernod.com/news/ophthalmology-off-the-grid-on-covid-19-part-2/2477441/In a move to provide ophthalmologists and eye care professionals a platform to share timely information during the COVID-19 outbreak, Bryn Mawr Communications (BMC) this week hosted its first live video webcast via Zoom and Facebook Live. The webcast, which was made through the company’s l
- American Academy of Optometry 2018 San Antonio Education Program Announcedhttps://modernod.com/news/american-academy-of-optometry-2018-san-antonio-education-program-announced/2480235/The American Academy of Optometry is pleased to announce highlights of the education program taking place at Academy 2018 San Antonio, November 7-10, 2018. The annual meeting offers a wide array of clinically relevant CE courses and cutting-edge research in the clinical and vision sciences. Atten
- Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-initial-clinical-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481028/Viridian Therapeutics announced positive initial clinical data from the 10mg/kg cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). The double-blind, placebo-controlled phase 1/2 trial is evaluating